Primary Sclerosing Cholangitis Market is Expected to Witness Increased Growth Over the Forecast Period (2022-2032), DelveInsight Reviews | Key Companies – Cilofexor, HTD1801, NGM282 (Aldafermin)

The “Primary Sclerosing Cholangitis Market Inspections, Epidemiology and Forecast 2032” report from DelveInsight offers an in-depth understanding of Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as Primary Sclerosing Cholangitis market trends to the United States, in the EU5 (Germany, Spain, Italy, France and United Kingdom) and in Japan.

The Primary Sclerosing Cholangitis Market is expected to rise due to the increasing prevalence and awareness of the disease over the forecast period. Additionally, the launch of various multi-stage primary sclerosing cholangitis pipeline products will significantly revolutionize the primary sclerosing cholangitis market dynamics.

Overview of Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is a rare cholestatic disorder of the liver, with narrowings of the bile ducts leading to cirrhosis of the liver in a proportion of patients. The etiology of PSC is unknown; thus, PSC is generally considered an idiopathic condition. Primary sclerosing cholangitis is often associated with inflammatory bowel disease and an increased risk of cholangitis carcinoma, gallbladder cancer, colorectal cancer, and hepatocellular carcinoma. Medical treatments are primarily aimed at symptom management, and disease-modifying treatments are limited. Endoscopic therapies are used in patients with dominant strictures and liver transplantation is a last resort.

Some of the key facts from the Primary Sclerosing Cholangitis Market report:

  • Primary Sclerosing Cholangitis Market Size Expected to Grow with Significant Growth CAGR during the study period (2019-2032)
  • The United States accounted for the largest primary sclerosing cholangitis market size, compared to EU5 (UK, Germany, Italy, France, and Spain) and Japan.
  • According to Gochanour et al., the prevalence in the United States is estimated at 1 to 16 per 100,000
  • According to Aune et al, primary sclerosing cholangitis is a rare disease with an incidence of 0.4-0.7 cases per 100,000 in the UK and a prevalence of 3.9-16.2 per 100,000
  • Main undertakings of primary sclerosing cholangitis: Gilead Sciences, High Tide Pty Ltd, NGM Biopharmaceuticals and others
  • Key therapies for primary sclerosing cholangitis: Cilofexor, HTD1801, NGM282 (Aldafermin) and others
  • Gender-based epidemiology of primary sclerosing cholangitis analyzed that men are more affected than women in cases of primary sclerosing cholangitis

Get Free Sample for Primary Sclerosing Cholangitis Market Report

Key Highlights of the Primary Sclerosing Cholangitis Market Report:

  1. The Primary Sclerosing Cholangitis Market report covers a descriptive overview and comprehensive overview of the Primary Sclerosing Cholangitis Epidemiology and Primary Sclerosing Cholangitis market in 7MM (US, EU5 (Germany, Spain, France , Italy, UK) and Japan.)
  2. The Primary Sclerosing Cholangitis market report provides insight into current and emerging therapies.
  3. The Primary Sclerosing Cholangitis Market report provides historical and forecast global market covering the spread of drugs in 7MM.
  4. The Primary Sclerosing Cholangitis Market report offers an advantage which will help in developing business strategies by understanding the trends shaping and driving the Primary Sclerosing Cholangitis market.

Learn More About Therapies Aimed to Capture Major Primary Sclerosing Cholangitis Market Share @ Primary Sclerosing Cholangitis Market Forecast

Segmentation of the epidemiology of primary sclerosing cholangitis:

The Primary Sclerosing Cholangitis market report offers epidemiological analysis for the study period 2019-2032 in 7MM segmented into:

  • Total prevalence of primary sclerosing cholangitis
  • Prevalent cases of primary sclerosing cholangitis by severity
  • Prevalence by sex of primary sclerosing cholangitis
  • Diagnosed cases of episodic and chronic primary sclerosing cholangitis

Primary Sclerosing Cholangitis Market

Primary Sclerosing Cholangitis market dynamics are expected to change in the coming years owing to the anticipated launch of emerging therapies such as HTD1801, NGM282and others during the forecast period 2019-2032.

Download the report to understand which factors drive the epidemiological trends of primary sclerosing cholangitis @ Epidemiological insights of primary sclerosing cholangitis

Primary Sclerosing Cholangitis Market Drivers

  • Market opportunity
  • Increase in research activities
  • Genome-wide association studies for primary sclerosing cholangitis

Primary sclerosing cholangitis therapies and key companies

  • Cilofexor: Gilead Sciences
  • HTD1801: High Tide Pty Ltd
  • NGM282 (Aldafermin): NGM Biopharmaceuticals

Scope of the Primary Sclerosing Cholangitis Market Report

  • Study period: 2019-2032
  • Cover: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Main undertakings of primary sclerosing cholangitis: Gilead Sciences, High Tide Pty Ltd, NGM Biopharmaceuticals and others
  • Key therapies for primary sclerosing cholangitis: Cilofexor, HTD1801, NGM282 (Aldafermin) and others
  • Therapeutic assessment of primary sclerosing cholangitis: Currently marketed primary sclerosing cholangitis and emerging therapies for primary sclerosing cholangitis
  • Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
  • Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies
  • Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement for Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis Market Barriers

  • Lack of country-specific epidemiological data
  • Trial shortcomings
  • Unavailability of biomarkers

Contents

1. Primary Sclerosing Cholangitis Market Report Introduction

2. Executive Summary for Primary Sclerosing Cholangitis

3. SWOT analysis of primary sclerosing cholangitis

4. Share of patients with primary sclerosing cholangitis (%) Overview at a glance

5. Primary Sclerosing Cholangitis Market Overview at a Glance

6. Background and disease overview of primary sclerosing cholangitis

7. Primary sclerosing cholangitis epidemiology and patient population

8. Patient population by country with primary sclerosing cholangitis

9. Current treatment of primary sclerosing cholangitis and medical practices

10. Unmet needs in primary sclerosing cholangitis

11. Emerging therapies for primary sclerosing cholangitis

12. Primary Sclerosing Cholangitis Market Outlook

13. Primary Sclerosing Cholangitis Market Analysis by Countries (2019-2032)

14. Access to the primary sclerosing cholangitis market and reimbursement of therapies

15. Primary Sclerosing Cholangitis Market Drivers

16. Primary Sclerosing Cholangitis Market Barriers

17. Appendix of primary sclerosing cholangitis

18. Primary sclerosing cholangitis reporting methodology

19. DelveInsight Abilities

20. Disclaimer

21. About DelveInsight

To learn more about the treatment of primary sclerosing cholangitis, visit @ Medications for primary sclerosing cholangitis

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Gaurav Bora
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About William G.

Check Also

Luxury Hotel Market Business Growth Strategies 2022-2028, by Size and Survey Caproate | Oberoi Hotels, Hilton Hotels

Luxury hotel market1 The luxury hotel market is expected to be driven by increasing growth …